Skip to main content

Newsroom press releases

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
Download

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
Download

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other
Download

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
Download

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
Download

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
Download

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
Download

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
Download

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)
Financial Data
Download

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
Products Molecular
Download

30/07/15 - 2:00

H1'15 Results (777.06 KB)
Financial Data
Download

20/07/15 - 2:00

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
Acquisition / Partnership
Download

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)
Products Immunodiagnostic
Download

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)
Financial Data
Download

12/05/15 - 2:00

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
Other
Download

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
Products Immunodiagnostic
Download

23/04/15 - 2:00

DiaSorin supports the Pinocchio Project (251.16 KB)
Download

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
Financial Data
Download

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)
Financial Data
Download

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
Products Immunodiagnostic
Download

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)
Financial Data
Download

24/03/15 - 1:00

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)
Download

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)
Financial Data
Download

24/02/15 - 1:00

DiaSorin supports Emergency in Sudan (612.64 KB)
Download

13/02/15 - 1:00

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)
Download

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.